Purpose: Immunohistochemical (IHC) evaluation is important for the management of breast cancer. Cold ischemic time (CIT) may result in inaccurate IHC results. The aim of this study was to investigate the effect of CIT on IHC results of invasive ductal carcinoma (IDC). Methods: We retrospectively reviewed the records of 316 patients diagnosed with IDC from February 2013 to June 2013 at a single hospital in Korea. The clinicopathological characteristics and IHC positivity for the estrogen receptor (ER), progesterone receptor (PR), Ki-67, and human epidermal growth factor receptor 2 (HER2) were compared between specimens with a CIT of ≤ 3 hours (short CIT) and those with a CIT of > 12 hours (long CIT). Results: Among the 316 patients, 227 had a CIT of ≤ 3 hours and 89 had a CIT of > 12 hours. No difference in positivity for ER (p= 0.734), PR (p= 0.870), and HER2 (p= 0.830) was observed between the two groups. In ER-positive specimens, the mean percentage value was higher in the long CIT group than in the short CIT group (81.3± 20.8% vs. 76.0± 26.3%, respectively; p= 0.021). The mean Ki-67 value was higher in the long CIT group compared to the short CIT group (9.7± 14.6% vs. 7.0± 10.8%, respectively; p= 0.047). Conclusion: CIT did not affect the positivity of ER, PR, HER2, and Ki-67 as determined by IHC when stored at 4°C overnight. However, specimens with a long CIT had a higher ER percentage value in ER-positive tumors and a higher Ki-67 value in all specimens compared to those with a short CIT. These differences should be considered in the interpretation of IHC results in specimens with a long CIT.
INTRODUCTION
Breast cancer is known for its well-established prognostic clinicopathological features such as age, tumor size, nodal status, grade, hormone receptor status, and human epidermal growth factor receptor 2 (HER2) status. Since the monumental meta-analysis of tamoxifen by the Early Breast Cancer Trialists' Collaborative Group in 1998 [1] , the introduction of antihormonal therapy has revolutionized breast cancer treatment, thereby resulting in better survival outcomes. In addition, after the approval of trastuzumab by the Food and Drug Administration in 2006 as part of an adjuvant treatment regimen for women with node-positive, HER2-overexpressing breast cancer, the target therapy agent has had a major impact in the treatment of HER2-positive breast cancer [2] . Immunohistochemical (IHC) evaluation of tumors is essential to guide treatment decisions using these therapeutic agents. Hormonal markers such as estrogen receptor (ER), progesterone receptor (PR), and markers of apoptosis and cell proliferation including Ki-67, bcl-2, and p53, as well as HER2, are common biomarkers evaluated by IHC [3, 4] .
The recent development of molecular diagnostic tools such as Oncotype DX Ⓡ (Genomic Health, Redwood City, USA) has provided additional prognostic information for systemic therapy decisions.
However, a prognostic model developed using the four IHC measurements of ER, PR, HER2, and Ki-67 has been shown to provide enough prognostic information, similar to that provided by Oncotype DX HER2, ER, and PR [6, 7] . According to the guidelines, the cold ischemic time (CIT) should be limited to less than 1 hour, and the samples should be fixed in 10% neutral buffered formalin for not less than 6
hours and not more than 72 hours for ER, PR, and HER2 testing.
In large-volume hospitals in Korea in which more than 1,500 breast cancer operations are performed every year, there is concern for time- 
METHODS
This retrospective study was approved by the Institutional Review
Board of Seoul National University Hospital (IRB number: 1306-006-493) and conducted in accordance with the Declaration of Helsinki.
The requirement for informed consent was waived.
Patients and variables
We retrospectively reviewed the records of 316 consecutive patients who underwent breast surgery for IDC from February 2013 to June 2013 at Department of Surgery of Seoul National University Hospital.
Patients who had received neoadjuvant chemotherapy were excluded.
Data about clinicopathological characteristics including age, type of surgery, tumor size, nodal status, nuclear grade, histologic grade, and pathologic stage were collected and analyzed. IHC staining was performed using the avidin-biotin complex technique for staining 4-μm-thick tissue sections from paraffin-embedded tissue blocks. The evaluation of ER, PR, HER2, and Ki-67 expression was performed by the same pathologist. The ER, PR, and HER2 status was determined according to the ASCO/CAP guidelines [8, 9] . A high expression of Ki-67 was defined as expression in ≥10% of tumor tissues, as the 10% cutoff provided the best predictive value for prognosis in our institution [10] . The methods used in this study are summarized in Figure 1 .
Definition of CIT
The surgically resected specimens were divided into two groups according to the CIT as determined by the length of time from the end of surgery to tissue fixation. The short CIT and long CIT groups were defined as CIT of ≤ 3 hours and CIT of >12 hours, respectively. The difference in CIT was mainly determined by whether the surgical specimen was formalin-fixed on the same day as the operation (CIT ≤ 3 hours) or on the following day (CIT >12 hours) after being stored overnight in a refrigerator at 4°C.
Statistical analysis
The chi-square test was used to observe the associations between 
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RESULTS
Among the 316 patients, 227 patients (71.8%) had a CIT of ≤ 3 hours 
DISCUSSION
In this study, we reviewed the records of 316 consecutive patients CIT = cold ischemic time; IHC = immunohistochemistry; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; BCS = breast-conserving surgery. *Mean ± SD. [15, 16] , where most showed a decrease in values. This may be explained by the fact that specimens with a long CIT were put in the refrigerator at 4°C with short exposure to room temperature, whereas some specimens with a short CIT were stored at room temperature for as long as 3 hours before being fixed. This may support the findings of previous studies where the IHC profile of refrigerated specimens was not affected by a long CIT [11] [12] [13] [14] . Furthermore, a wide range of CIT in the short CIT group may have prevented specific evaluation of specimens with CIT of ≤1 hour.
Some limitations of this study are the retrospective nature of data collection and the small number of specimens evaluated. In addition, the definition of CIT is arbitrary, being judged by whether the specimen was fixed on the operation day or the following day. Further prospective, large-scale studies with detailed grouping of CIT are needed for a more accurate evaluation of the effect of CIT on IHC findings.
In conclusion, CIT did not affect the positivity of ER, PR, HER2, and
Ki-67 as determined by IHC when stored at 4°C overnight. However, specimens with a long CIT had a higher ER percentage value in ERpositive tumors and a higher Ki-67 value in all specimens compared to those with a short CIT. These differences should be considered in the interpretation of IHC results in specimens with a long CIT.
